Navigation Links
Prolong Pharmaceuticals Adds Industry Veteran Ronald Jubin To Executive Management Team
Date:12/18/2013

SOUTH PLAINFIELD, N.J., Dec. 18, 2013 /PRNewswire/ -- Prolong Pharmaceuticals LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical costs and mortality, today announced the addition of Ronald G. Jubin, Ph.D. to their executive team as Managing Director, Research and Development. In his new role, Dr. Jubin will be responsible for pre-clinical discovery, methods development and the advancement of Prolong's pipeline candidates.

(Logo:  http://photos.prnewswire.com/prnh/20130926/NY87531LOGO )

"Ron brings more than two decades of experience at the forefront of drug discovery to our efforts here at Prolong," said Dr. Abraham Abuchowski, Prolong's Chief Scientific Officer and CEO. "We are excited to bring him on board at this important time in our company history." In October, Prolong presented Phase I data for its flagship product SANGUINATE an intravenous therapeutic that combines the beneficial functions of a carbon monoxide releasing molecule with an oxygen transfer agent as well as acting as a plasma expander. SANGUINATE was found to be well tolerated with no serious adverse events, and is now moving forward into Phase II trials in patients with sickle cell disease who suffer from painful vaso-occlusive crises. 

Dr. Jubin's experience includes key roles at Schering-Plough Research Institute and PBL Biomedical labs. At Schering-Plough, he served in major roles in the hepatitis C protease program, directed other HCV inhibitor programs and managed internal committees evaluating novel interferon candidate licensing opportunities. At PBL Biomedical, his tenure leading the R&D department at PBL resulted in the development of numerous interferon proteins, reagents and functional assay for evaluating immune and interferon functions.  Dr. Jubin received his Ph.D. in Microbiology and Molecular Genetics from the UMDNJ-NJMS Graduate School of Biomedical Sciences, Newark, NJ.

"This is an opportunity to work with the inventors of the world's leading drug delivery technology, PEGYLATION, at its birthplace here in New Jersey," said Dr. Jubin. "This is the sort of environment where historic, groundbreaking drug developments occur, and I am looking forward to being a part of the leadership team." 

About Sanguinate

SANGUINATE is an investigational biopharmaceutical product that has a multiple mechanisms of action designed to release therapeutic carbon monoxide and actively transfer oxygen to hypoxic tissue. SANGUINATE has completed Phase I safety trials and is beginning trials in SCD patients.

About Prolong Pharmaceuticals 

Headquartered in South Plainfield, New Jersey, Prolong Pharmaceuticals LLC is developing products to treat several diseases and their debilitating comorbidities which cause reduced quality of life, increased medical cost and significant mortality. The company's lead product, SANGUINATE™, is in clinical testing, focused on treating the comorbidities of sickle cell disease and other disorders where oxygen deprivation due to hemolysis and/or ischemia occurs.  The company's senior management team includes inventors of the most successful drug delivery technology in pharmaceutical history, PEGylation, now responsible for more than $30 billion in drug sales worldwide. For more information visit: www.prolongpharma.com.


'/>"/>
SOURCE Prolong Pharmaceuticals LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
2. Prolong TM, a New Revolutionary First Line Treatment for Premature Ejaculation is Licensed in Europe
3. Prolong Pharmaceuticals Presents Novel Multi-Pronged Approach To Treating Sickle Cell Disease At The SCDAA Meeting
4. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
7. BioElectronics Survey Indicates a Five-Fold Superior Pain Relief Compared to OTC Pharmaceuticals
8. Icahn Issues Statement Regarding Amylin Pharmaceuticals
9. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
10. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
11. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... England , January 19, 2017 ... and Otsuka in the Milner Therapeutics Consortium   ... scientists in Cambridge   ... (NYSE: PFE ) as a partner to ... the Consortium, which enables the efficient transfer of materials ...
(Date:1/19/2017)... 2017  ViewRay, Inc. (Nasdaq: VRAY ... clinical MRI-guided radiation therapy system, announced today that it ... million through a private placement of its common ... financing and was joined by certain of ViewRay,s ... Venture Partners, and an additional new institutional investor, ...
(Date:1/19/2017)... , Jan. 18, 2017 The Academy ... and Drug Administration (FDA) for its release today ... population health decision makers can proactively share clinical ... as well as emerging therapies awaiting FDA approval. ... consensus recommendations that AMCP developed during two multi-stakeholder ...
Breaking Medicine Technology:
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... acoustic and privacy panel system. , The Tranquility privacy panel system was ... collaborative office environment. Tranquility panels help reduce noise and provide the visual privacy ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Sam & Associates ... to commercial and residential clients in the California Bay Area, is launching a charity ... in the region. , Heart disease is the primary killer of adult men and ...
(Date:1/19/2017)... ... 19, 2017 , ... For the third year running, Noto ... the surrounding area, is inaugurating a charity event to help raise funds ... Lou Gehrig's disease or motor neurone disease, is a deadly neurological disorder that ...
(Date:1/19/2017)... ... January 19, 2017 , ... Creative messages ... Real Impact contest from Impact Teen Drivers and California Casualty. Entries from students ... , Educational grants totaling $15,000 will be awarded for the best peer-to-peer messages ...
(Date:1/19/2017)... San Diego, CA (PRWEB) , ... January 19, 2017 , ... ... for their 2017 collaboration with the American Heart Association; “Howe” Healthy is Your ... how to stay healthy and active. Each year, Bill Howe Plumbing, Heating & Air ...
Breaking Medicine News(10 mins):